Edgewise Therapeutics (NASDAQ:EWTX) Announces Earnings Results

Posted by Geri Gentry on Nov 4th, 2026

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) released its earnings results on Wednesday. The company reported $0.84 EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $1.36, Zacks reports.

Edgewise Therapeutics Price Performance

Shares of NASDAQ EWTX traded down $0.15 during trading hours on Wednesday, reaching $37.53. 1,053,821 shares of the stock were exchanged, compared to its average volume of 1,360,565. The stock’s fifty day simple moving average is $41.08 and its 200 day simple moving average is $36.34. Edgewise Therapeutics has a 52 week low of $16.70 and a 52 week high of $48.51.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EWTX. Oppenheimer initiated coverage on Edgewise Therapeutics in a report on Thursday, July 9th. They set an “outperform” rating and a $51.00 price objective on the stock. Wall Street Zen upgraded shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, October 4th. HC Wainwright reaffirmed a “buy” rating on shares of Edgewise Therapeutics in a research note on Wednesday, October 14th. Evercore reiterated an “outperform” rating and issued a $55.00 price target on shares of Edgewise Therapeutics in a report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.33.

Check Out Our Latest Analysis on EWTX

Insider Transactions at Edgewise Therapeutics

In other news, CMO Joanne M. Donovan sold 6,522 shares of Edgewise Therapeutics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.85, for a total transaction of $285,989.70. Following the completion of the sale, the chief marketing officer owned 11,544 shares of the company’s stock, valued at approximately $506,204.40. This trade represents a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel John Moore sold 5,016 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $43.82, for a total transaction of $219,801.12. Following the transaction, the general counsel directly owned 17,697 shares in the company, valued at $775,482.54. This represents a 22.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 38,329 shares of company stock valued at $1,675,529. Corporate insiders own 21.30% of the company’s stock.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for severe muscle disorders. The company’s research programs target the biology of skeletal and cardiac muscle, with the goal of addressing diseases for which treatment options remain limited.

Edgewise’s lead product candidate is sevasemten (formerly EDG-5506), an oral therapy designed to reduce contraction-induced muscle damage associated with dystrophinopathies, including Duchenne and Becker muscular dystrophy.